However, several recent studies from different labs identified several candidates, including STAT1, the E3 ubiquitin ligase DTX3L (also known as B-lymphoma and BAL-associated protein (BBAP)) and the B-aggressive lymphoma protein and mono-ADP-ribosyltransferase ARTD9 (also known as BAL1 or PARP9), which may be essentially required for the observed chemotherapy resistance in HR-DLBCL and also play a role in editing or inhibiting the host immune response against HR-DLBCL [469, 470, 473]. Here, PARP9 is linked to diffuse large B-cell lymphoma.